SIGN UP

David Ricks, Eli Lilly CEO (Al Drago/Bloomberg via Getty Images)

February 7, 2024 11:29 AM ESTUpdated 11:57 AM

Lilly CEO raises concerns about Novo-Catalent buy, calling the Novo Nordisk deal ‘unusual’

Anna Brown

News Reporter

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Takeda announces handful of pipeline cuts in effort to ‘pivot resources’

GSK awaits Nucala decision after FDA target date passes

AI-focused biotech insitro cuts 22% of staff, citing 'tumultuous market'

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

AstraZeneca loses appeals court fight over IRA drug price negotiations

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges